申请人:MedImmune Limited
                            
                            
                                公开号:US10576164B2
                            
                            
                                公开(公告)日:2020-03-03
                            
                            
Conjugate compounds of formula (A):
wherein:
R2 is
where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester;
R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo;
R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo;
Y is selected from formulae A1, A2, A3, A4, A5 and A6:
L is a linker connected to a cell binding agent;
CBA is the cell binding agent;
n is an integer selected in the range of 0 to 48;
RA4 is a C1-6 alkylene group;
either
(a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or
(b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or
(c) R10 is H and R11 is OSOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation;
R and R′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
wherein R16, R17, R19, R20, R21 and R22 are as defined for R6, R7, R9, R10, R11 and R2 respectively;
wherein Z is CH or N;
wherein T and T′ are independently selected from a single bond or a C1-9 alkylene, which chain may be interrupted by one or more heteroatoms e.g. O, S, N(H), NMe, provided that the number of atoms in the shortest chain of atoms between X and X′ is 3 to 12 atoms;
and
X and X′ are independently selected from O, S and N(H).
                            式(A)的共轭化合物:
其中
R2 是
其中 R36a 和 R36b 独立选自 H、F、C1-4 饱和烷基、C2-3 烯基,这些烷基和烯基任选被选自 C1-4 烷基
氨基和 C1-4 烷基酯的基团取代;或者,当 R36a 和 R36b 中的一个为 H 时,另一个选自腈和 C1-4 烷基酯;
R6 和 R9 独立地选自 H、R、OH、OR、SH、SR、NH2、NHR、NRR′、
NO2、Me3Sn 和卤素;
R7 独立选自 H、R、OH、OR、SH、SR、NH2、NHR、NRR′、   、Me3Sn 和卤素;
Y 选自式 A1、A2、A3、A4、A5 和 A6:
L 是与细胞结合剂相连的连接体;
CBA 是细胞结合剂;
n 是选自 0 至 48 之间的整数;
RA4 是 C1-6 烷基;
或者
(a) R10 是 H,R11 是 OH、ORA,其中 RA 是 C1-4 烷基;或
(b) R10 和 R11 所结合的氮原子和碳原子之间形成氮碳双键;或
(c) R10 为 H,R11 为 OSOzM,其中 z 为 2 或 3,M 为一价药学上可接受的阳离子;
R 和 R′各自独立地选自任选取代的 C1-12 烷基、C3-20 杂环基和 C5-20 芳基,并且任选与基团 NRR′、R 和 R′连同它们所连接的氮原子一起形成任选取代的 4、5、6 或 7 元杂环;
其中 R16、R17、R19、R20、R21 和 
R22 分别如 R6、R7、R9、R10、R11 和 R2 所定义;
其中 Z 是 CH 或 N
其中 T 和 T′独立地选自单键或 C1-9 亚烷基,该链可被一个或多个杂原子如 O、S、N(H)、NMe 中断,条件是 X 和 X′之间最短原子链中的原子数为 3 至 12 个原子;
和
X 和 X′独立地选自 O、S 和 N(H)。